DRE Quality Assurance & Improvement 2 — Questions and Answers
Question 1: When a DRE's evaluation is later found to be inconsistent with toxicology results, what is the MOST appropriate quality assurance response?
- Discard the toxicology results as unreliable
- Conduct a case review to identify potential training or procedural gaps (Correct answer)
- Remove the DRE from active duty permanently
- Suppress the inconsistency to protect the program's credibility
Correct answer: Conduct a case review to identify potential training or procedural gaps
Case reviews of inconsistent outcomes are a core QA tool for identifying systemic issues and improving future DRE performance.
Question 2: Which metric is MOST useful for tracking the overall accuracy of a DRE program over time?
- Number of evaluations completed per month
- Percentage of DRE drug category opinions confirmed by toxicology (Correct answer)
- Total number of trained DREs in the jurisdiction
- Average time required to complete a 12-step evaluation
Correct answer: Percentage of DRE drug category opinions confirmed by toxicology
Toxicology confirmation rates directly measure how accurately DREs identify drug categories, making it the primary accuracy metric.
Question 3: A DRE supervisor notices that one evaluator consistently misses CNS depressant indicators. The BEST corrective action is:
- Reassign the DRE to non-drug cases
- Provide targeted retraining focused on CNS depressant recognition (Correct answer)
- Require the DRE to repeat the entire initial DRE course
- Refer the DRE to the IACP for decertification
Correct answer: Provide targeted retraining focused on CNS depressant recognition
Targeted retraining addresses the specific knowledge or skill gap without the unnecessary disruption of full recertification.
Question 4: In the context of DRE QA, a 'blind review' of a Drug Influence Report (DIR) means:
- The reviewer reads the DIR without knowing the toxicology results (Correct answer)
- The DRE completes the evaluation without lighting in the examination room
- The supervisor reviews the case without informing the DRE
- The toxicologist evaluates the subject before the DRE does
Correct answer: The reviewer reads the DIR without knowing the toxicology results
A blind review prevents confirmation bias by ensuring the reviewer assesses the DIR's quality independent of the known toxicology outcome.
Question 5: Which of the following represents a systemic QA issue rather than an individual DRE error?
- One DRE forgets to document pupil size on a single evaluation
- Multiple DREs across a region consistently fail to identify inhalants (Correct answer)
- A single DRE's handwriting is illegible on one DIR
- One DRE arrives late to a call-out three times in a year
Correct answer: Multiple DREs across a region consistently fail to identify inhalants
When the same error appears across multiple evaluators, it signals a systemic training or procedural deficiency rather than individual fault.
Question 6: Peer review in a DRE quality assurance program PRIMARILY serves to:
- Rank DREs competitively to determine promotion eligibility
- Provide a collegial mechanism for identifying and sharing best practices (Correct answer)
- Replace the need for supervisor oversight entirely
- Produce legally admissible documentation for court proceedings
Correct answer: Provide a collegial mechanism for identifying and sharing best practices
Peer review leverages experienced DREs to identify procedural improvements and share effective techniques in a non-punitive environment.
Question 7: According to DRE program standards, how frequently should a certified DRE conduct evaluations to maintain proficiency?
- At least once per year
- At least four evaluations per year (Correct answer)
- At least one evaluation per month
- At least 50 evaluations over a 2-year recertification cycle
Correct answer: At least four evaluations per year
IACP/NHTSA standards require DREs to conduct a minimum of four drug evaluations annually to maintain hands-on proficiency.
DRE Quality Assurance & Improvement 2
When a DRE's evaluation is later found to be inconsistent with toxicology results, what is the MOST appropriate quality assurance response?